Disclosures: Susanne Pors: Nothing to Disclose, Jacob Nhr-Meldgaard: Nothing to Disclose, Kristoffer Voldum-Clausen: Nothing to Disclose, Anitta Kinga Sarvari: Nothing to Disclose, Sakthi Jagadeesan: Nothing to Disclose, Kasper Almholt: Nothing to Disclose, Natalia Petersen: Novo Nordisk: Employee, Charlotta Dornonville de la Cour: Novo Nordisk A/S: Employee, Sebastian Beck Jrgensen: Nothing to Disclose, Henrik Hansen: Nothing to Disclose, Michael Feigh: Nothing to Disclose 1035 ACYL-COA THIOESTERASE 12-MEDIATED PPAR&GAMMA
Most existing cardiovascular outcome trials were not designed with BP as the primary outcome, and variations in BP measurements, drug doses, and trial designs limit cross-study comparisons
Women with pre-existing diabetes during pregnancy should have A1C levels measured during pregnancy to assist in management
In the multivariable analysis, the risk of intrahepatic recurrence was similar between the Tx-maintained and Tx-nave groups (hazard ratio [HR], 1.09